Current Report Filing (8-k)
May 16 2017 - 8:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2017
BioDelivery Sciences International, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-31361
|
|
35-2089858
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
4131 ParkLake Ave., Suite #225
Raleigh, NC
|
|
27612
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
919-582-9050
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the filing
obligation to the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act
(17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act
(17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01.
|
Other Information.
|
On May 15, 2017, BioDelivery Sciences International, Inc. (the
Company) issued a press release announcing that the Company had filed its Quarterly Report on Form
10-Q
for the quarter ended March 31, 2017 and providing an update on the Companys
business operations, recent accomplishments and anticipated milestones for the year 2017. A copy of the press release is attached as Exhibit 99.1 hereto.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
99.1
|
|
Press release, dated May 15, 2017, announcing the filing of the Companys Quarterly Report and business operations, recent accomplishments and anticipated milestones.
|
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form
8-K,
the press release included herein, and any statements of representatives and partners
of BioDelivery Sciences International, Inc. (the Company) related thereto contain, or may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Companys plans, objectives, projections, expectations and intentions and other
statements identified by words such as projects, may, will, could, would, should, believes, expects, anticipates, estimates,
intends, plans, potential or similar expressions. These statements are based upon the current beliefs and expectations of the Companys management and are subject to significant risks and uncertainties,
including those detailed in the Companys filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Companys development, commercialization and strategic initiatives) may differ
significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Companys control).
The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
May 16, 2017
|
|
|
|
BIODELIVERY SCIENCES INTERNATIONAL, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Ernest R. De Paolantonio
|
|
|
|
|
|
|
Name:
|
|
Ernest R. De Paolantonio
|
|
|
|
|
|
|
Title:
|
|
Chief Financial Officer, Secretary and Treasurer
|
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Apr 2024 to May 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From May 2023 to May 2024